Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „ibrutinib“
Suchtreffer
Begriffe & Kennungen
Rhapsido · 4.5 · Active substances that may increase remibrutinib blood concentrations
Eintrag öffnenRhapsido · 4.5 · Active substances whose plasma concentrations may be altered by remibrutinib
Eintrag öffnenRhapsido · 4.5 · CYP3A4 inducers Co-administration of remibrutinib with strong or moderate CYP3A4 inducers must be avoided. Co-
Eintrag öffnenRhapsido · 4.5 · CYP3A4 inhibitors Co-administration of remibrutinib with strong CYP3A4 inhibitors must be avoided. Co-administ
Eintrag öffnenRhapsido · 4.5 · Effect of remibrutinib on antithrombotic agents
Eintrag öffnenRhapsido · 4.5 · Effect of remibrutinib on immune response to vaccines
Eintrag öffnenRhapsido · 4.5 · No data are available on co-administration of remibrutinib with anticoagulants. The risks and benefits of co-a
Eintrag öffnenRhapsido · 4.5 · No data are available on the effects of live or live-attenuated vaccines in patients receiving remibrutinib an
Eintrag öffnenRhapsido · 4.5 · Oral contraceptives Co-administration of remibrutinib is not expected to have an adverse impact on the efficac
Eintrag öffnenRhapsido · 4.5 · Remibrutinib is primarily metabolised by CYP3A4.
Eintrag öffnenRhapsido · 4.5 · Vaccination immune response study In a placebo-controlled study in healthy volunteers using remibrutinib 100 m
Eintrag öffnenRhapsido · 4.8 · In patients treated with remibrutinib, 0.5% experienced mucocutaneous bleeding events that led to remibrutinib
Eintrag öffnenRhapsido · 4.8 · The safety profile of remibrutinib in patients treated for up to 52 weeks in REMIX-1 and REMIX-2 remained cons
Eintrag öffnenVenclyxto · 4.5 · Ibrutinib
Eintrag öffnenVenclyxto · 4.5 · In studies of ibrutinib (420 mg) in combination with venetoclax (400 mg) in CLL patients, an increase in venet
Eintrag öffnenVenclyxto · 4.8 · In the venetoclax + ibrutinib arm in the GLOW study, all-grade neutropenia/neutrophil count decreased was repo
Eintrag öffnenVenclyxto · 4.8 · The frequencies of adverse reactions reported with Venclyxto, in combination with obinutuzumab, ibrutinib, or
Eintrag öffnenibrutinib
Eintrag öffnenremibrutinib
Eintrag öffnenremibrutinib
Eintrag öffnen